The shot is the lead product candidate from BioNTech's FixVac platform and is based on a combination of four mRNA-encoded, melanoma-associated antigens – NY-ESO-1, MAGE-A3, tyrosinase ...
It has KITE-439, a TCR therapy directed against the human papillomavirus and KITE-718, a TCR therapy directed against MAGE A3 and MAGE A6, antigens frequently found in solid tumours including ...
This project has not set up a SECURITY.md file yet.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback